Making cells 'younger' works differently in each cell type, study finds

Scientists have been chasing a tempting idea: briefly push an old cell toward a younger state, then stop before it forgets what it is, and leave it both rejuvenated and still doing its normal job. A new preprint posted on 12 November 2026 reports that this does not play out the same way for every cell. In human cells grown in a dish, the balance between gaining youth and keeping function depended heavily on the type of cell.¹

The work, by Washizu, Wang, Draper, Yamanaka and Kunitomi, is a preprint, meaning it has been shared publicly before other scientists have formally reviewed it. Its results are in cells, not people.¹

What the researchers did

The team used a technique called partial reprogramming. It borrows a set of molecules known as Yamanaka factors, which can wind a mature cell back toward the flexible, unspecialised state of a stem cell. Done fully, that process erases what a cell is and can form tumours, so researchers only want a brief, partial version that captures the rejuvenation without the cell losing its identity.²

Part of the appeal is a change in what scientists call the cell’s epigenetic pattern. That is the set of chemical tags sitting on top of a cell’s DNA, acting like switches that turn genes on and off. These tags drift with age, and one widely used clock reads them to estimate how old a cell looks. Partial reprogramming can push that reading back toward a younger value.³²

In this study, the researchers used a reversible, trackable system so they could switch the reprogramming on, catch cells at intermediate points along the way, then switch it off and watch what happened next. They did this in three kinds of primary human cells: skin cells (fibroblasts), a type of immune cell (cytotoxic T cells), and the cells that line blood vessels (aortic endothelial cells).¹

Each cell type behaved differently

The outcomes split apart. Skin cells held on to a younger reading on that DNA-tag clock, but they kept behaving like scar-forming, tissue-remodelling cells and did not fully regain their ability to divide. In other words, they looked younger by one measure but did not bounce all the way back.¹

Immune cells were fussier. They only recovered when the reprogramming had been light. Pushed too far, they did not come back. But from a shallow nudge, they returned with stronger fighting ability.¹

Blood-vessel cells came out best in this comparison. They quickly regained their normal identity, kept a younger reading on the clock, and worked noticeably better at their vascular job.¹

A shared switch, different downstream effects

Looking under the hood, the team found that a gene called TOX was a shared dependency: cells needed it to move along the reprogramming path, whatever their type. When the researchers dialled TOX down in experiments, it affected how the cells progressed. But the programs TOX appeared to control further downstream were mostly specific to each cell type rather than common across all of them.¹

They also report that none of these results lined up with how efficiently the same cells could be turned fully into stem cells. That matters because efficiency of full conversion is a common yardstick in the field; here it did not predict which cells kept the benefit or recovered well.¹

What it does not show

This is laboratory work on cells, posted as a preprint. It has not been peer reviewed, and it was not tested in a living animal or person. The study does not claim that any cell was made to live longer or that a disease was treated. It measures a chemical-age reading, cell behaviour and recovery in a dish, and it describes a trade-off, not a cure.¹

The headline message from the authors is a caution as much as a result: partial reprogramming involves a cell-type-specific trade-off between rejuvenation and recovery that, in their words, “must be optimized one lineage at a time.” A single recipe is unlikely to suit every tissue.¹

How it fits the wider field

The broader goal of separating rejuvenation from a loss of cell identity is not new. Earlier work in mouse and human cells identified gene-activity signatures of reprogramming and suggested the youthful effects could, at least in part, be pulled apart from the stem-cell transformation that carries the tumour risk.³

Partial reprogramming has already moved toward the clinic in one narrow setting. In January 2026, a gene therapy from Life Biosciences, known as ER-100, became the first reprogramming-based rejuvenation therapy to clear a key US regulatory step allowing human testing, according to one explainer.² The registered early-stage trial is injecting it into the eye in adults with certain optic-nerve conditions, with an estimated 18 participants, and is designed mainly to check safety.⁴ That effort targets one tissue in one organ. The new preprint helps explain why such a focused approach may be necessary: what works for one cell type may not transfer to another.¹

What to watch next

The useful next steps would be independent peer review of this preprint, attempts by other labs to repeat the cell-type differences, and any sign that the same split shows up in living tissue rather than a dish. The eye trial will also report its first safety data in time; its primary completion is listed for May 2027, with participants followed for up to five years.⁴ Until then, the practical takeaway from this study is narrow but clear: in human cells, “making a cell younger” is not one problem but several, and each cell type may need its own answer.¹